SVB Leerink reiterated coverage on Amicus Therapeutics with a new price target

2/24/22 1:15:50 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

SVB Leerink reiterated coverage of Amicus Therapeutics with a rating of Outperform and set a new price target of $14.00 from $16.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$FOLD

Date	Price Target	Rating	Analyst
12/13/2024	$17.00 → $12.00	Overweight → Equal-Weight	Morgan Stanley
9/6/2024	$18.00	Buy	Jefferies
5/30/2024	$18.00	Overweight	Wells Fargo
5/14/2024	$13.00	Neutral → Buy	Guggenheim
12/19/2023	$15.00 → $20.00	Equal-Weight → Overweight	Morgan Stanley
9/9/2022	$14.00	Equal-Weight	Morgan Stanley
4/13/2022	$11.00	Neutral	Goldman
2/24/2022	$16.00 → $14.00	Outperform	SVB Leerink